New device aims to help NMOSD patients walk better
NCT ID NCT06374264
First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This study tests a device called MR-C-014 that uses sound to help people with neuromyelitis optica spectrum disorder (NMOSD) who have trouble walking. Thirty adults will use the device for 30 minutes, three times a week for 8 weeks. The main goals are to see if people find it acceptable and safe, and to measure any changes in walking distance.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MR-C-014 (a rhythmic auditory stimulation device)
- What this could lead to
- If it works, this could point toward a non-drug way to improve walking and endurance in people with NMOSD.
- What could go wrong
- This is a very small, early feasibility study with only 30 participants. It is not designed to prove the device works, only that it is safe and acceptable. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18-70 years of age (inclusive). 2. Able to read and/or understand English. 3. Meets revised diagnostic criteria for NMOSD proposed by the International Panel for NMO Diagnosis (IPND) in 2015. 4. Past clinical history of Transverse Myelitis as seen on imaging or as determined by clinical review by the investigator. 5. Demonstrates an observable gait deficit resulting from a diagnosis of NMOSD as determined by the Investigator or medical history review. 6. Currently able to walk at a speed greater or equal to 0.4 m/s, but less than 1.5 m/s, as determined by walking speed during a Timed 25-Foot Walk Test (T25FWT) (cane(s), walking stick(s), crutch(es), wheeled walker, external functional neuromuscular stimulator(s), and ankle foot orthosis allowed). a. Note: if assistive devices are planned to be used during the Intervention Phase walking sessions, they should be used during the Screening, Baseline, and Closing visit gait assessments as well. 7. Has a reciprocal gait pattern. a. Note: a non-reciprocal gait pattern is defined as a 3-point step pattern. Participants must have a 2-point step pattern to qualify. Asymmetry seen in gait is acceptable. 8. Ability and willingness to provide Informed Consent. Exclusion Criteria: 1. Unable or unwilling to comply with study protocol. 2. People who become pregnant or are pregnant (due to expected changes in gait patterns). 3. Unable to safely participate in protocol-defined walking sessions of 30-minute duration as determined by the investigator. 4. Significant co-morbid medical or neurological disease or injury, or treatment for such conditions that currently affects, or has potential to affect, participant gait for safety during participation in the study as determined by the investigator. 5. Has an external lower limb prosthetic ("artificial limb"). 6. Initiated physical therapy for lower limb in the past 4 weeks or anticipated to start due to safety concerns (e.g., falls). 7. Requires at least one seated rest during the T25FWT. 8. Initiation, change, or discontinuation of disease-modifying therapy in the past 3 months known to affect gait (e.g., dalfampridine, corticosteroid, medications for spasticity). 9. Recent NMOSD relapse (last 3 months) and/or hospitalization. 10. Severe hearing impairment with or without the use of hearing aids, such that the participant cannot hear the rhythmic music stimulus consistently, as determined by participant and investigator. 11. Treatment with a gait-based investigational intervention within the last 3 months. Enrollment in observational studies is allowed. 12. Vulnerable populations as deemed inappropriate for study by investigator. For this protocol, vulnerable persons are considered to be those who are relatively (or absolutely) incapable of protecting their own interests.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neuromyelitis optica spectrum disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Sheperd Center
Atlanta, Georgia, 30309, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Genetic clues may forecast multiple sclerosis after vision loss
- Engineered immune cells take aim at autoimmune diseases
- Can virtual training rewire the brain in MS?
- New study aims to understand physical challenges in kids with nerve diseases
- Experimental CAR t treatment targets root cause of rare nerve disease